Sanara MedTech (SMTI)
Makes surgical repair products for soft tissue and bone fusion.
Something off on this page? Send us feedback.
Sells surgical products for soft tissue repair and bone fusion, with CellerateRX-led collagen, wound-irrigation, graft, extracellular-matrix, and bone-matrix offerings. After discontinuing THP, the business reports one surgical-market segment focused mainly on North American hospitals and surgery centers.
Develops and commercializes surgical products used in operating rooms and other sterile settings, mainly in the North American surgical tissue repair market. The current portfolio centers on soft tissue repair products such as CellerateRX Surgical Powder, BIASURGE, TEXAGEN, FORTIFY TRG, and FORTIFY FLOWABLE, alongside BiFORM, ACTIGEN, and ALLOCYTE Plus bone fusion products.
Sales execution depends on hospital and surgery-center access, field representatives, distributors, and contracted or approved facility coverage. Rochal Technologies supports in-house R&D for the company's Prepare, Promote and Protect surgical strategy.
Reporting now reflects one surgical-market segment after THP, a value-based wound-care services initiative, was discontinued. The business depends on product adoption by surgeons and compliance with regulated medical-product channels.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jul 30, 2026 | Lake Street | Downgrade | Buy | Hold | $32 | $35 |
| Jul 30, 2026 | H.C. Wainwright | Downgrade | Buy | Neutral | $54 | $35 |
| Jul 30, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral | ||
| Apr 15, 2026 | Lake Street | Target | $32 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $15.4M · Total debt $48.5M · Total assets $69.1M · Shareholders' equity $7.9M
- Revenue
- $28.1M
- Operating income
- $1.8M
- Net income
- −$452.9K
No dividends on record.
| Institutions65 holders · as of Mar 31, 2026 | 16.25% | 1.49M shares | |
| Insiders14 holders · as of Jun 5, 2026 | 4.42% | 405.7K shares | |
| Otherremainder | 79.33% | 7.29M shares |
9.19M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Tall Pines Capital, LLCInstitution | 5.58% | 512,872 | 13Gfiled Oct 8, 2024 ↗ |
BlackRock, Inc.Institution | 2.49% | 228,767 | 13Fas of Mar 31, 2026 |
Vanguard Capital Management LLCInstitution | 1.65% | 151,367 | 13Fas of Mar 31, 2026 |
Stonebridge Wealth Management, LLCInstitution | 1.49% | 136,899 | 13Fas of Mar 31, 2026 |
Royal Bank of CanadaInstitution | 1.43% | 131,389 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Integra LifeSciences
Regenerative tissue and collagen matrices for surgical repair
- BD
Ready-to-use surgical irrigation system in the operating room
- Solventum
Advanced wound dressings, NPWT, and incision-care portfolio
- MiMedx
Placental allografts for advanced wound and surgical use
- Organogenesis
Regenerative advanced wound care and surgical biologics
- Globus Medical
Spine and orthopedic biologics with bone graft substitutes
- Stryker
Large orthopedic biologics platform for grafting and matrices
- TELA Bio
Reinforced tissue matrices for soft-tissue reconstruction
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Sanara MedTech | $34.31 | −1.41% | $319.9M | — | 71.5 | 2.9 | +8.9% |
| Integra LifeSciences | $16.88 | +0.42% | $1.31B | — | 6.6 | 0.8 | +0.8% |
| BD | $189.24 | +0.88% | $51.67B | 56.5 | 14.2 | 2.5 | −9.6% |
| Solventum | $91.90 | −0.01% | $15.91B | 11.2 | 13.6 | 1.9 | +2.2% |
| MiMedx | $4.56 | +1.00% | $663.2M | 113.8 | 107.3 | 1.9 | −34.7% |
| Organogenesis | $1.68 | +0.56% | $214.9M | — | — | 0.5 | −56.7% |
| Globus Medical | $80.41 | −0.30% | $10.88B | 20.7 | 15.8 | 3.5 | +5.9% |
| Stryker | $314.00 | +0.58% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| TELA Bio | $0.7510 | −5.09% | $33.7M | — | — | 0.4 | −4.5% |
| Median | 32.4 | 15.0 | 1.9 | −1.9% |